Background/Aim: Glioblastomas (GBMs) are the most malignant primary brain tumor. New treatment strategies against the disease are urgently needed, as therapies are not completely efficient. In this study, we evaluated the antitumorigenic activity of the carotenoid fucoxanthin (Fx) on human GBM cells in vitro. Materials and Methods: GBM1 cell viability and proliferation was assessed by MTT reduction, Ki67 and single cell cloning assays. GBM1 migration and invasion were analyzed by wound healing and Transwell assays. Apoptosis and necrosis were analyzed by flow cytometry, and the mitochondrial membrane potential (ΔΨm) by the selective fluorescent dye tetramethylrhodamine ethyl ester. Cell morphology was analyzed through scanning electron microscopy and transmission electron microscopy. Fx anti-angiogenic effect was assessed by the CAM ex ovo assay. Results: Fx decreased cell viability in a concentration-dependent manner (40-100 μ M) in GBM1, A172 and C6 cell lines and was not cytotoxic to murine astrocytes. In addition, Fx inhibited the proliferation and clonogenic potential, and decreased migration and invasion of GBM1 cells. Furthermore, Fx induced apoptosis, loss of ΔΨm and ultrastructural alterations in GBM1. Fx-treated GBM1 cells-conditioned medium reduced the quail yolk membrane vascularity.
Conclusion: Fx induces cytotoxicity, anti-proliferative, antiinvasive and anti-angiogenic effects on GBM1 cells.Gliomas are primary tumors that affect the central nervous system (CNS). The origin of glioma cells is not completely elucidated, and may derive from dedifferentiation of a mature cell type, glial progenitor cells or primitive neural stem cells (1). The primary malignant brain neoplasms global-gender incidence rate is approximately 2.6 per 100,000 for females and 3.7 per 100,000 for males, per year (2). Gliomas compose only 27% of all CNS primary neoplasms, however, it represents almost 80% of all malignant primary tumors that affect this system (3,4).Gliomas are histopathologically categorized by the World Health Organization (WHO) into different subtypes and grades (I to IV), as oligodendroglioma, oligoastrocytoma and astrocytoma. Grade IV is reserved for a subtype of astrocytoma, the glioblastoma (GBM) (5). GBM is the most malignant glioma and the most frequent primary cerebral tumor, with an incidence of 3.2 cases per 100,000 person/year 6799